Ivabradine Accord

Ivabradine, the active ingredient in Ivabradine Accord, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate by selectively inhibiting the funny current in the sinoatrial node and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Ivabradine acts on cardiac chronotropy by selectively inhibiting the If current, and is used in the following clinical settings: - Chronic stable angina: improves exercise tolerance and reduces frequency of angina attacks. - Heart failure with reduced ejection fraction: lowers heart rate to improve ventricular filling and symptoms. - Coronary artery disease where heart‑rate reduction is desired: helps control myocardial oxygen demand.

Ivabradine may cause a range of adverse reactions. Monitoring for side effects is part of routine clinical care.

Common Side Effects: - Luminous phenomena (phosphenes): transient visual disturbances. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Visual disturbances persisting beyond transient episodes. - Heart block. - Severe allergic reaction (anaphylaxis).

Before initiating ivabradine, clinicians should consider several safety aspects. - Cardiac monitoring: obtain baseline ECG and heart‑rate assessment. - Bradycardia risk: avoid use in patients with resting heart rate <60 bpm. - CYP3A4 inhibitors: dose adjustment may be required when co‑administered. - Pregnancy and lactation: use only if potential benefit justifies the risk. - Renal/hepatic impairment: start with lower dose and monitor closely. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine plasma levels. - Concomitant bradycardic agents (e.g., beta‑blockers, diltiazem): can cause excessive heart‑rate reduction. - Other If channel inhibitors: additive effect on heart‑rate control.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise ivabradine concentrations. - Drugs that prolong QT interval: increase risk of cardiac arrhythmias. - Antihypertensive agents: may enhance blood‑pressure lowering effect.